HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Negotiations

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Since this article was published last December, Net Pricing Drug Channel developments have accelerated. Manufacturers reduced the list prices

By Drug Channels · Apr 8, 2026 · via Drug Channels
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

Photo: Pexels

This is an aggregated industry headline. Read the full story at Drug Channels →

Tags
policyformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Negotiations
All Negotiations →
NegotiationsDrug Channels ↗
PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (VIDEO)
Here at Drug Channels, we’ve been closely tracking the evolution of the pharmacy benefit management (PBM) indu…
May 20, 2026
Amgen expands crackdown on what it says is misuse of 340B program
NegotiationsEndpoints News ↗
Amgen expands crackdown on what it says is misuse of 340B program
Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal dru…
May 15, 2026
Optum Rx unveils pharmacy model with clear fees, building on transparency push
NegotiationsEndpoints News ↗
Optum Rx unveils pharmacy model with clear fees, building on transparency push
UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said off…
May 11, 2026